VistaGen Therapeutics, Inc. (VTGN)

NASDAQ: VTGN · IEX Real-Time Price · USD
0.129
-0.009 (-6.44%)
At close: Mar 20, 2023, 4:00 PM
0.132
+0.003 (2.17%)
After-hours: Mar 20, 2023, 7:58 PM EDT
-6.44%
Market Cap 30.06M
Revenue (ttm) -363,900
Net Income (ttm) -63.71M
Shares Out 232.67M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,317,372
Open 0.140
Previous Close 0.138
Day's Range 0.125 - 0.140
52-Week Range 0.080 - 1.790
Beta 1.10
Analysts Sell
Price Target 0.20 (+54.8%)
Earnings Date Feb 7, 2023

About VTGN

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 34
Stock Exchange NASDAQ
Ticker Symbol VTGN
Full Company Profile

Financial Performance

In 2022, VTGN's revenue was $1.11 million, an increase of 1.78% compared to the previous year's $1.09 million. Losses were -$48.71 million, 15.1% more than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for VTGN stock is "Sell." The 12-month stock price forecast is $0.2, which is an increase of 54.80% from the latest price.

Price Target
$0.2
(54.80% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individual...

1 week ago - Business Wire

Vistagen to Present at Cowen 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

2 weeks ago - Business Wire

Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

2 weeks ago - Business Wire

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for th...

1 month ago - Zacks Investment Research

Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

1 month ago - Business Wire

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

1 month ago - Business Wire

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

1 month ago - Business Wire

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,...

1 month ago - Business Wire

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

2 months ago - Business Wire

Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

2 months ago - Business Wire

Vistagen to Acquire Pherin Pharmaceuticals

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

3 months ago - Business Wire

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,...

3 months ago - Business Wire

Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

3 months ago - Business Wire

Vistagen Announces Publication in Cells Demonstrating AV-101's Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,...

4 months ago - Business Wire

What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock

VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 months ago - Zacks Investment Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

4 months ago - Zacks Investment Research

Vistagen Reports Second Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

4 months ago - Business Wire

Vistagen to Present at Stifel 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif.

4 months ago - Business Wire

Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the ...

5 months ago - Business Wire

Vistagen to Participate at Cantor Neurology & Psychiatry Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

6 months ago - Business Wire

Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

6 months ago - Business Wire

Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals li...

6 months ago - Business Wire